Regenerex Pharma (Regenerex Pharma) Change In Receivables : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Regenerex Pharma Change In Receivables?

Regenerex Pharma's change in receivables for the quarter that ended in Dec. 2023 was $0.00 Mil. It means Regenerex Pharma's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .

Regenerex Pharma's change in receivables for the fiscal year that ended in Mar. 2023 was $0.00 Mil. It means Regenerex Pharma's Accounts Receivable stayed the same from Mar. 2022 to Mar. 2023 .

Regenerex Pharma's Accounts Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Regenerex Pharma's liquidation value for the three months ended in Dec. 2023 was $-4.72 Mil.

Regenerex Pharma Change In Receivables Historical Data

The historical data trend for Regenerex Pharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenerex Pharma Change In Receivables Chart

Regenerex Pharma Annual Data

Trend

Nov09

Nov10

Nov11

Nov12

Nov13

Nov14

Mar17

Mar18

Mar22

Mar23

Change In Receivables

Get a 7-Day Free Trial

Regenerex Pharma Quarterly Data
	May14	Aug14	Nov14	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Regenerex Pharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Regenerex Pharma (OTCPK:PEPT) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Regenerex Pharma's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Regenerex Pharma's accounts receivable are only considered to be worth 75% of book value:

Regenerex Pharma's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.008	-	4.728	+	0.75 * 0	+	0.5 * 0
=	-4.72

Regenerex Pharma Change In Receivables Related Terms

Thank you for viewing the detailed overview of Regenerex Pharma's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenerex Pharma (Regenerex Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Regenerex Pharma Inc (OTCPK:PEPT) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

5348 Vegas Drive, Suite 177, Las Vegas, NV, USA, 89108

Website

https://regenerexpharmainc.com

Regenerex Pharma Inc develops and markets Woundcare Healing products. The current product technology provides the Company with a number of complete wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns, and surgical wounds. Its product Xcellderma OTC a Liquid Bandage Skin Protectant Xcellderma products are sterile wound dressings for treating diabetic foot ulcers, pressure ulcers, and other chronic wounds; Accelerex Sterile Wound Cream is for the treatment of a wide variety of chronic and acute wounds; and Accelerex Impregnated Sterile Wound Dressing use as a wound dressing to manage pressure ulcers (stages I-IV), stasis ulcers, diabetic skin ulcers, skin irritations, cuts, and abrasions.

Regenerex Pharma (Regenerex Pharma) Headlines

No Headlines